Anti-RNF11 antibody [EPR6820]

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RNF11 antibody [EPR6820] (AB154831)

Immunohistochemical analysis of paraffin-embedded Human kidney tissue labeling RNF11 with ab154831 at 1/50 dilution.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• WB

Unknown

Western blot - Anti-RNF11 antibody [EPR6820] (AB154831)

All lanes:

Western blot - Anti-RNF11 antibody [EPR6820] (ab154831) at 1/1000 dilution

Lane 1:

MCF7 cell lysate at 10 µg

Lane 2:

Human fetal liver tissue lysate at 10 µg

Secondary

All lanes:

Goat anti-rabbit HRP conjugated at 1/2000 dilution

Predicted band size: 17 kDa,30 kDa

false

• Flow Cyt (Intra)

Unknown

Flow Cytometry (Intracellular) - Anti-RNF11 antibody [EPR6820] (AB154831)

Intracellular flow cytometric analysis of permeabilized MCF7 cells labeling RNF11 with ab154831 at 1/100 dilution (red) compared to a rabbit IgG negative control (green).

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-RNF11 antibody [EPR6820] (AB154831)

Immunohistochemical analysis of paraffin-embedded Human brain tissue labeling RNF11 with ab154831 at 1/50 dilution.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• WB

CiteAb

Western blot - Anti-RNF11 antibody [EPR6820] (AB154831)

RNF11 western blot using anti-RNF11 antibody [EPR6820] ab154831. Publication image and figure legend from Sa, J. K., Hong, J. Y., et al., 2020, Genome Med, PubMed 32070411.

ab154831 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab154831 please see the product overview.

Transcriptome correlates of gefitinib sensitivity. a Elastic-net regression results of transcriptome features that predict pharmacological response to gefitinib. The bottom scatter plot represents drug response for gefitinib-treated tumors. The upper heatmap shows the top extracted features in the model. The left bar graph shows the averaged weight of each predictive feature. The number of appearances in 100 bootstraps is indicated in parentheses. b Scatter plot revealing a linear correlation between gefitinib AUC and RNF11 transcriptome expression. Correlation coefficients and P values were obtained by Pearson correlation analysis. c Immunoblot analysis of RNF11, p-EGFR, EGFR in gastric cancer cell-lines. β-Actin was used as a loading control (left panel). Cell proliferation assay in EGFR-activated gastric cancer cell-lines (right panel). Cancer cells were exposed to gefitinib for 72 h, and then, cell viability was measured. d Gastric cancer cell-lines with high (SNU5; left panel) and low (SNU638; right panel) RNF11 expression were transiently transfected with 10 nM of siRNF11 and treated with gefitinib for 72 h the next day. The results are represented as the mean ± SD of triplicate wells and are representative of three independent experiments. e Immunoblot analysis of EGFR signaling-related molecules, including p-EGFR, EGFR, p-AKT, and AKT in gastric cancer cell-lines that were transiently transfected with 10 nM of siRNF11 and treated with gefitinib for 4 h the next day. P values in c, d were derived from two-sided Student’s t tests

false